Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
A. Zanghì & E. D’Amico. (2019) New treatment targets in multiple sclerosis therapy. Expert Review of Precision Medicine and Drug Development 4:4, pages 201-203.
Read now
Read now
Fiona Costello & Jodie M Burton. (2018) Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?. Eye and Brain 10, pages 47-63.
Read now
Read now
Alberto Gajofatto & Marco Turatti. (2018) Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs 27:3, pages 273-286.
Read now
Read now
Articles from other publishers (20)
Omid Jamshidi Kandjani, Shadi Yaqoubi, Samad Shams Vahdati, Behnam Borhannejad, Siavoush Dastmalchi & Ali Akbar Alizadeh. (2023) S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. European Journal of Medicinal Chemistry 250, pages 115182.
Crossref
Crossref
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, RoshanaVander Wall, Rashi Rajput, Kanishka Pushpitha, Samridhi Sharma, Mehdi Mirzaei, Alexander Klistorner & StuartL Graham. (2023) Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. Neural Regeneration Research 18:4, pages 840.
Crossref
Crossref
Nicolas Collongues, Guillaume Becker, Valérie Jolivel, Estelle Ayme-Dietrich, Jérôme de Seze, Fabien Binamé, Christine Patte-Mensah, Laurent Monassier & Ayikoé Guy Mensah-Nyagan. (2022) A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. Neurology and Therapy 11:3, pages 981-1042.
Crossref
Crossref
Klaudia Sapko, Anna Jamroz-Wiśniewska & Konrad Rejdak. (2022) Novel Drugs in a Pipeline for Progressive Multiple Sclerosis. Journal of Clinical Medicine 11:12, pages 3342.
Crossref
Crossref
Marika Alborghetti, Gianmarco Bellucci, Antonietta Gentile, Chiara Calderoni, Ferdinando Nicoletti, Ruggero Capra, Marco Salvetti & Diego Centonze. (2022) Drugs Used in the Treatment of Multiple Sclerosis During COVID-19
Pandemic: A Critical Viewpoint. Current Neuropharmacology 20:1, pages 107-125.
Crossref
Crossref
Donald J. AbrahamWilliam J. Pitts & Alaric J. Dyckman. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
43
.
Faik Imeri, Bisera Stepanovska Tanturovska, Aleksandra Zivkovic, Gaby Enzmann, Stephanie Schwalm, Josef Pfeilschifter, Thomas Homann, Burkhard Kleuser, Britta Engelhardt, Holger Stark & Andrea Huwiler. (2021) Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis. Neuropharmacology 186, pages 108464.
Crossref
Crossref
Jerold Chun, Gavin Giovannoni & Samuel F. Hunter. (2020) Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs 81:2, pages 207-231.
Crossref
Crossref
Katherine A. Owen, Andrew Price, Hannah Ainsworth, Bryce N. Aidukaitis, Prathyusha Bachali, Michelle D. Catalina, James M. Dittman, Timothy D. Howard, Kathryn M. Kingsmore, Adam C. Labonte, Miranda C. Marion, Robert D. Robl, Kip D. Zimmerman, Carl D. Langefeld, Amrie C. Grammer & Peter E. Lipsky. (2020) Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries. The American Journal of Human Genetics 107:5, pages 864-881.
Crossref
Crossref
Bisera Stepanovska, Aleksandra Zivkovic, Gaby Enzmann, Silvia Tietz, Thomas Homann, Burkhard Kleuser, Britta Engelhardt, Holger Stark & Andrea Huwiler. (2020) Morpholino Analogues of Fingolimod as Novel and Selective S1P1 Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis. International Journal of Molecular Sciences 21:18, pages 6463.
Crossref
Crossref
Haibo Mei, Jianlin Han, Sarah White, Daniel J. Graham, Kunisuke Izawa, Tatsunori Sato, Santos Fustero, Nicholas A. Meanwell & Vadim A. Soloshonok. (2020) Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry – A European Journal 26:50, pages 11349-11390.
Crossref
Crossref
Zizhen Yin, Wenfei Hu, Wei Zhang, Hiroyuki Konno, Hiroki Moriwaki, Kunisuke Izawa, Jianlin Han & Vadim A. Soloshonok. (2020) Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. Amino Acids 52:9, pages 1227-1261.
Crossref
Crossref
Tjalf Ziemssen, Olaf Hoffmann, Luisa Klotz, Herbert Schreiber, Martin S Weber & Benedict Rauser. (2020) Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. JMIR Research Protocols 9:7, pages e19598.
Crossref
Crossref
Emanuela Colombo, Claudia Bassani, Anthea De Angelis, Francesca Ruffini, Linda Ottoboni, Giancarlo Comi, Gianvito Martino & Cinthia Farina. (2020) Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration. Frontiers in Immunology 11.
Crossref
Crossref
Syed A. Rizvi. 2020. Clinical Neuroimmunology. Clinical Neuroimmunology
137
157
.
Shinji Oki. (2019) Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation. Neurochemistry International 130, pages 104348.
Crossref
Crossref
Tomasz Grzegorski & Jacek Losy. (2019) Multiple sclerosis – the remarkable story of a baffling disease. Reviews in the Neurosciences 30:5, pages 511-526.
Crossref
Crossref
Mar Tintore, Angela Vidal-Jordana & Jaume Sastre-Garriga. (2018) Treatment of multiple sclerosis — success from bench to bedside. Nature Reviews Neurology 15:1, pages 53-58.
Crossref
Crossref
Joana Machado-Santos, Etsuji Saji, Anna R Tröscher, Manuela Paunovic, Roland Liblau, Galina Gabriely, Christian G Bien, Jan Bauer & Hans Lassmann. (2018) The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain 141:7, pages 2066-2082.
Crossref
Crossref
Shinji Oki. (2018) Novel mechanism and biomarker of chronic progressive multiple sclerosis. Clinical and Experimental Neuroimmunology 9:1, pages 25-34.
Crossref
Crossref